Efgartigimod - Open Access .click

Results 41 to 50 of about 1,204 (125)

Myasthenia Gravis (MG) Resource Utilization, Epidemiology, Survival, and Treatment Patterns (MG‐REST): Estimating the Clinical and Economic Burden in Ontario, Canada

European Journal of Neurology, Volume 33, Issue 8, August 2026.
A cohort of patients living with myasthenia gravis (MG) in Ontario (n = 2601) were identified using health administrative data (2013–2020) to estimate burden of illness. MG prevalence increased from 36 to 42 per 100,000 over the study period. 5‐year survival was 75% overall and 39% among patients experiencing myasthenic crisis (8.9% of patients ...
Carolina Barnett‐Tapia +7 more
wiley +1 more source

Current advances in 2025: A critical review of selected topics by the Association for the Advancement of Blood and Biotherapies (AABB) Clinical Transfusion Medicine Committee

Transfusion, EarlyView.
Nabiha H. Saifee +24 more
wiley +1 more source

Age and Treatment Efficacy in Myasthenia Gravis: A Systematic Review, Meta‐Analysis, and Meta‐Regression

European Journal of Neurology, Volume 33, Issue 8, August 2026.
Across 18 randomized trials involving 1823 participants, active therapies improved both QMG and MG‐ADL outcomes versus control. Trial‐level meta‐regression showed that each 10‐year increase in mean baseline age was associated with a 1.21‐point smaller QMG benefit, explaining 25.4% of between‐trial heterogeneity; the association appeared strongest in ...
Christopher Nelke +4 more
wiley +1 more source

Oral Corticosteroid and Nonsteroidal Immunosuppressant Therapy Use in Patients with Myasthenia Gravis Receiving Ravulizumab, Eculizumab, or Efgartigimod in the USA

Neurology and Therapy
Introduction Oral corticosteroids (OCSs) and nonsteroidal immunosuppressant therapies (NSISTs) remain widely used for the clinical management of patients with generalized myasthenia gravis (gMG), despite well-documented risks.
Francesco Saccà +4 more
doaj +1 more source

Efficacy and Safety of Subcutaneous Efgartigimod PH20 in Adults With Primary Immune Thrombocytopenia (ADVANCE SC): A Multicenter, Randomized, Double‐Blinded, Placebo‐Controlled, Phase 3 Trial

American Journal of Hematology, Volume 101, Issue 7, Page 1494-1506, July 2026.
ABSTRACT Primary autoimmune thrombocytopenia (ITP) is characterized by thrombocytopenia, bleeding, and reduced health‐related quality of life. In the Phase 3 ADVANCE IV study, intravenous efgartigimod induced significant platelet count responses versus placebo in patients with chronic ITP. ADVANCE SC, a Phase 3, multicenter, randomized, double‐blinded,
Nichola Cooper +546 more
wiley +1 more source

Add-on efgartigimod in myasthenic crisis: a promising treatment option

Frontiers in Neurology
BackgroundIn myasthenia crisis (MC), plasma exchange (PE) and intravenous immunoglobulin (IVIG) are confirmed effective treatment options, but PE may not be available in time, and the response rate to IVIG is not always satisfactory.
Fangyi Shi +35 more
doaj +1 more source

Digital Phenotyping and Lifestyle Intervention in Patients With Myasthenia Gravis (DIG‐MG): A Randomized Controlled Trial of Feasibility, Adherence, and Effects on Fatigue

Muscle &Nerve, Volume 74, Issue 1, Page 92-102, July 2026.
ABSTRACT Introduction/Aims Physical activity and sleep influence fatigue in myasthenia gravis (MG), and digital health technologies (DHT) enable objective monitoring of these behaviors in daily life. Using this approach, we evaluated whether a lifestyle intervention targeting physical activity or sleep hygiene could reduce fatigue in MG.
Maja Norling +9 more
wiley +1 more source

Evolving treatments for Sjögren disease: current approaches and emerging targets

Internal Medicine Journal, Volume 56, Issue 7, Page 1126-1133, July 2026.
Abstract Sjögren disease (SjD) is a prevalent systemic autoimmune condition characterised by exocrine gland dysfunction, systemic inflammation and heterogeneous organ involvement. Current management remains largely symptomatic, with no approved disease‐modifying therapies available and substantial unmet clinical need. However, advances in understanding
Mansi Bhurani +3 more
wiley +1 more source

Fast-acting treatment of myasthenic crisis with efgartigimod from the perspective of the neuro intensive care unit

BMC Neurology
Background Myasthenic crisis (MC) refers to rapid deterioration of myasthenia gravis (MG), affecting lung and bulbar muscles and causing breathing difficulties.
Fangyi Shi +9 more
doaj +1 more source

Comparison of intravenous efgartigimod and intravenous immunoglobulin in patients with Guillain–Barré syndrome

Orphanet Journal of Rare Diseases
Objective This study aimed to compare the effectiveness of intravenous efgartigimod and intravenous immunoglobulin (IVIg) in patients with Guillain–Barré syndrome (GBS).
Huiqiu Zhang +10 more
doaj +1 more source

myasthenia gravis
myasthenic crisis
immunoglobulin g

diseases of the nervous system
neurology
fcrn inhibitor

neonatal fc receptor
treatment
antibody